Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pomalidomide + bortezomib + low-dose dexamethasone versus bortezomib + low-dose dexamethasone in relapsed or refractory multiple myeloma
NL-OMON44661Phase 3Active, not recruiting
- Sponsor
- Celgene Corporation
- Start
- Jan 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Pomalidomide + bortezomib + low-dose dexamethasone with Bortezomib + low-dose dexamethasone (2 arms). Primary endpoint: Progression-free survival. Started Jan 2013; status: active, not recruiting.
02
Drugs
pomalidomidebortezomibdexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON44661.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44661.